Literature DB >> 17974529

Glucagonoma with two pancreatic masses and pulmonary metastases as debut of MEN-1.

V Gutiérrez1, M Cobo, D Olea, J García, C Ramírez, D Bautista, J Alcalde.   

Abstract

This is a rare case of a patient with type 1 multiple endocrine neoplasia (MEN-1) syndrome. The case is further unusual in that the glucagonoma debuted with two synchronic pancreatic masses at the time of diagnosis and with pulmonary metastases as the primary site of metastasis and not the more usual site of the liver.

Entities:  

Mesh：

Year:  2007        PMID： 17974529     DOI： 10.1007/s12094-007-0121-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  13 in total

Review 1.  Pancreatic endocrine tumors.

Authors:  J Chun; G M Doherty
Journal:  Curr Opin Oncol       Date:  2001-01       Impact factor: 3.645

2.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry.

Authors:  Nathalie Lévy-Bohbot; Corinne Merle; Pierre Goudet; Brigitte Delemer; Alain Calender; Damien Jolly; Gérard Thiéfin; Guillaume Cadiot
Journal:  Gastroenterol Clin Biol       Date:  2004-11

Review 4.  The glucagonoma syndrome: a review of its features and discussion of new perspectives.

Authors:  M A Chastain
Journal:  Am J Med Sci       Date:  2001-05       Impact factor: 2.378

5.  Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.

Authors:  P Tomassetti; M Migliori; R Corinaldesi; L Gullo
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

6.  High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.

Authors:  B Eriksson; J Renstrup; H Imam; K Oberg
Journal:  Ann Oncol       Date:  1997-10       Impact factor: 32.976

7.  Surgical strategy for large or malignant endocrine pancreatic tumors.

Authors:  P Hellman; M Andersson; J Rastad; C Juhlin; S Karacagil; B Eriksson; B Skogseid; G Akerström
Journal:  World J Surg       Date:  2000-11       Impact factor: 3.352

8.  Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment.

Authors:  D Grama; B Skogseid; E Wilander; B Eriksson; H Mårtensson; B Cedermark; B Ahrén; A Kristofferson; K Oberg; J Rastad
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

9.  Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach.

Authors:  Juan M Sarmiento; Florencia G Que; Clive S Grant; Geoffrey B Thompson; Michael B Farnell; David M Nagorney
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

Review 10.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871
View more
  2 in total

1.  Application of Somatostatin, Chemotherapy Combined with TAE in Heterogeneous Glucagonoma Presented with Necrolytic Migratory Erythema.

Authors:  Chaoyong Shen; Jiaoxue He; Xiaoyan Le; Linmao Zheng; Dan Cao
Journal:  Onco Targets Ther       Date:  2019-12-20       Impact factor: 4.147

2.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.